Safety and Immunogenicity of an HIV-1 Prefusion-stabilized Envelope Trimer (Trimer 4571) Vaccine in Healthy Adults: A First-in-human Open-label, Randomized, Dose-escalation, Phase 1 Clinical Trial

Background: Advances in therapeutic drugs have increased life-expectancies for HIV-infected individuals, but the need for an effective vaccine remains. We assessed safety and immunogenicity of HIV-1 vaccine, Trimer 4571 (BG505 DS-SOSIP.664) adjuvanted with aluminum hydroxide (alum), in HIV-negative adults.

Methods: We conducted a phase I, randomized, open-label, dose-escalation trial at the National Institutes of Health Clinical Center in Bethesda, MD, USA. Eligible participants were HIV-negative, healthy adults between 18-50 years. Participants were randomized 1:1 to receive Trimer 4571 adjuvanted with 500 mcg alum by either the subcutaneous (SC) or intramuscular (IM) route at weeks 0, 8, and 20 in escalating doses of 100 mcg or 500 mcg. The primary objectives were to evaluate the safety and tolerability of Trimer 4571 with a secondary objective of evaluating vaccine-induced antibody responses. The primary and safety endpoints were evaluated in all participants who received at least one dose of Trimer 4571. Trial results were summarized using descriptive statistics. This trial is registered at ClinicalTrials.gov, NCT03783130.

Findings: Between March 7 and September 11, 2019, 16 HIV-negative participants were enrolled, including six (38%) males and ten (62%) females. All participants received three doses of Trimer 4571. Solicited reactogenicity was mild to moderate in severity, with one isolated instance of severe injection site redness (6%) following a third 500 mcg SC administration. The most commonly reported solicited symptoms included mild injection site tenderness in 14 (88%) and mild myalgia in six (38%) participants. The most frequent unsolicited adverse event attributed to vaccination was mild injection site pruritus in six (38%) participants. Vaccine-induced seropositivity occurred in seven (44%) participants and resolved in all but one (6%). No serious adverse events occurred. Trimer 4571-specific binding antibodies were detected in all groups two weeks after regimen completion, primarily focused on the glycan-free trimer base. Neutralizing antibody activity was limited to the 500 mcg dose groups.

Interpretation: Trimer 4571 was safe, well tolerated, and immunogenic in this first-in-human trial. While this phase 1 trial is limited in size, our results inform and support further evaluation of prefusion-stabilized HIV-1 envelope trimers as a component of vaccine design strategies to generate broadly neutralizing antibodies against HIV-1.

Funding: Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Citing Articles

The membrane-proximal external region of human immunodeficiency virus (HIV-1) envelope glycoprotein trimers in A18-lipid nanodiscs.

Qi Y, Zhang S, Wang K, Ding H, Zhang Z, Anang S Commun Biol. 2025; 8(1):442.

PMID: 40089599 DOI: 10.1038/s42003-025-07852-z.

Rational design of next-generation filovirus vaccines with glycoprotein stabilization, nanoparticle display, and glycan modification.

Lee Y, Zhang Y, Newby M, Ward G, Gomes K, Auclair S bioRxiv. 2025; .

PMID: 40060701 PMC: 11888476. DOI: 10.1101/2025.03.02.641072.

Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth.

Pollock K, Cheeseman H, McFarlane L, Day S, Tolazzi M, Turner H EBioMedicine. 2025; 112:105544.

PMID: 39753033 PMC: 11753977. DOI: 10.1016/j.ebiom.2024.105544.

Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for Vaccines.

Khudainazarova N, Granovskiy D, Kondakova O, Ryabchevskaya E, Kovalenko A, Evtushenko E Int J Mol Sci. 2024; 25(22).

PMID: 39596049 PMC: 11594041. DOI: 10.3390/ijms252211979.

Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.

Hahn W, Parks K, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L J Exp Med. 2024; 221(10).

PMID: 39235529 PMC: 11380150. DOI: 10.1084/jem.20240604.

References

Cheng C, Duan H, Xu K, Chuang G, Corrigan A, Geng H . Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. Cell Rep. 2020; 32(5):107981. PMC: 11075050. DOI: 10.1016/j.celrep.2020.107981. View

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

Chuang G, Lai Y, Boyington J, Cheng C, Geng H, Narpala S . Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. J Virol. 2020; 94(13). PMC: 7307166. DOI: 10.1128/JVI.00074-20. View

Gulla K, Cibelli N, Cooper J, Fuller H, Schneiderman Z, Witter S . A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation. Vaccine. 2021; 39(25):3379-3387. PMC: 8243839. DOI: 10.1016/j.vaccine.2021.04.063. View

Overbaugh J, Morris L . The Antibody Response against HIV-1. Cold Spring Harb Perspect Med. 2012; 2(1):a007039. PMC: 3253031. DOI: 10.1101/cshperspect.a007039. View

Ou L, Kong W, Chuang G, Ghosh M, Gulla K, ODell S . Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen. Sci Rep. 2020; 10(1):3032. PMC: 7033230. DOI: 10.1038/s41598-020-59711-y. View

Sanders R, Derking R, Cupo A, Julien J, Yasmeen A, de Val N . A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013; 9(9):e1003618. PMC: 3777863. DOI: 10.1371/journal.ppat.1003618. View

Struwe W, Chertova E, Allen J, Seabright G, Watanabe Y, Harvey D . Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen. Cell Rep. 2018; 24(8):1958-1966.e5. PMC: 6113929. DOI: 10.1016/j.celrep.2018.07.080. View

Kwong P, DeKosky B, Ulmer J . Antibody-guided structure-based vaccines. Semin Immunol. 2020; 50:101428. DOI: 10.1016/j.smim.2020.101428. View

10.

Fauci A, Lane H . Four Decades of HIV/AIDS - Much Accomplished, Much to Do. N Engl J Med. 2020; 383(1):1-4. DOI: 10.1056/NEJMp1916753. View

11.

Corrigan A, Duan H, Cheng C, Gonelli C, Ou L, Xu K . Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. Cell Rep. 2021; 35(1):108937. PMC: 8070658. DOI: 10.1016/j.celrep.2021.108937. View

12.

Pancera M, Zhou T, Druz A, Georgiev I, Soto C, Gorman J . Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014; 514(7523):455-61. PMC: 4348022. DOI: 10.1038/nature13808. View

13.

Ivleva V, Cooper J, Arnold F, Lei Q . Overcoming Challenges in Structural Characterization of HIV-1 Envelope Glycoprotein by LC-MS/MS. J Am Soc Mass Spectrom. 2019; 30(9):1663-1678. PMC: 7476438. DOI: 10.1007/s13361-019-02225-3. View

14.

Binley J, Sanders R, CLAS B, Schuelke N, Master A, Guo Y . A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol. 2000; 74(2):627-43. PMC: 111582. DOI: 10.1128/jvi.74.2.627-643.2000. View

15.

Graham B, Keefer M, McElrath M, Gorse G, Schwartz D, Weinhold K . Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med. 1996; 125(4):270-9. DOI: 10.7326/0003-4819-125-4-199608150-00003. View

16.

Decker J, Bibollet-Ruche F, Wei X, Wang S, Levy D, Wang W . Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med. 2005; 201(9):1407-19. PMC: 2213183. DOI: 10.1084/jem.20042510. View

17.

Kong R, Xu K, Zhou T, Acharya P, Lemmin T, Liu K . Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science. 2016; 352(6287):828-33. PMC: 4917739. DOI: 10.1126/science.aae0474. View

18.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R . Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361(23):2209-20. DOI: 10.1056/NEJMoa0908492. View

19.

Flynn N, Forthal D, Harro C, Judson F, Mayer K, Para M . Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005; 191(5):654-65. DOI: 10.1086/428404. View

20.

Kwon Y, Pancera M, Acharya P, Georgiev I, Crooks E, Gorman J . Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol. 2015; 22(7):522-31. PMC: 4706170. DOI: 10.1038/nsmb.3051. View